CUSIP No. 2332 4Q 202 Page 1 of XX
1. Names of Reporting Persons.
Daniel Gannon
2. Check the Appropriate Box if a Member of a Group
(a) [ ]
(b) [ ]
3. SEC Use Only
4. Source of Funds (See Instructions)
PF
5. Check if Disclosure of Legal Proceedings Is Required Pursuant
to Items 2(d) or 2(e)
[ ]
6. Citizenship or Place of Organization
United States
Number of Shares Beneficially Owned by Each Reporting Person With:
7. Sole Voting Power
219,113,367
8. Shared Voting Power
0
9. Sole Dispositive Power
219,113,367
10. Shared Dispositive Power
0
11. Aggregate Amount Beneficially Owned by Each Reporting Person
219,113,367
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares
[ ]
13. Percent of Class Represented by Amount in Row (11)
16.9%
14. Type of Reporting Person
IN
ITEM 1. SECURITY AND ISSUER
State the title of the class of equity securities to which this
statement relates and the name and address of the principal executive
offices of the issuer of such securities.
Common Stock
DNAPrint Genomics, Inc.
1621 West University Parkway
Sarasota, FL 34243
ITEM 2. IDENTITY AND BACKGROUND
(a) Name;
Daniel Gannon
(b) Residence or business address;
P.O. Box 90638, Portland, Oregon 97290
(c) Present principal occupation or employment and the name,
principal business and address of any corporation or other
organization in which such employment is conducted;
Individual Investor
(d) Whether or not, during the last five years, such person
has been convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors) and, if so, give the dates,
nature of conviction, name and location of court, and penalty
imposed, or other disposition of the case;
Not applicable.
(e) Whether or not, during the last five years, such person was
a party to a civil proceeding of a judicial or administrative body
of competent jurisdiction and as a result of such proceeding was
or is subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to,
federal or state securities laws or finding any violation with
respect to such laws; and, if so, identify and describe such
proceedings and summarize the terms of such judgment, decree or
final order; and
Not applicable.
(f) Citizenship.
United States
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
Personal Funds
$ 126,009.63
ITEM 4. PURPOSE OF TRANSACTION
Investment purpose.
(a) The acquisition by any person of additional securities of
the issuer, or the disposition of securities of the issuer;
Continuing trading on the open market.
(b) An extraordinary corporate transaction, such as a merger,
reorganization or liquidation, involving the issuer or any of
its subsidiaries;
Not applicable.
(c) A sale or transfer of a material amount of assets of the
issuer or any of its subsidiaries;
Not applicable.
(d) Any change in the present board of directors or management
of the issuer, including any plans or proposals to change the
number or term of directors or to fill any existing vacancies
on the board;
Not applicable.
(e) Any material change in the present capitalization or dividend
policy of the issuer;
Not applicable.
(f) Any other material change in the issuer's business or corporate
structure including but not limited to, if the issuer is a
registered closed-end investment company, any plans or proposals to
make any changes in its investment policy for which a vote is required
by section 13 of the Investment Company Act of 1940;
Not applicable.
(g) Changes in the issuer's charter, bylaws or instruments
corresponding thereto or other actions which may impede the
acquisition of control of the issuer by any person;
Not applicable.
(h) Causing a class of securities of the issuer to be delisted
from a national securities exchange or to cease to be authorized to
be quoted in an inter-dealer quotation system of a registered national
securities association;
Not applicable.
(i) A class of equity securities of the issuer becoming eligible for
termination of registration pursuant to Section 12(g)(4) of the Act; or
Not applicable.
(j) Any action similar to any of those enumerated above.
Not applicable.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
(a) State the aggregate number and percentage of the class of
securities identified pursuant to Item 1
219,113,367
16.9%
(b)
Sole Voting Power:
219,113,367
Shared Voting Power:
0
Sole Dispositive Power:
219,113,367
Shared Dispositive Power:
0
(c) Describe any transactions in the class of securities reported
on that were effected during the past sixty days or since the most
recent filing of Schedule 13D (ss.240.13d-191), whichever is less,
by the persons named in response to paragraph (a).
Since my most recent filing of Schedule 13D, I, Daniel Gannon, have purchased
20,701,580 shares at the price of $0.0004, on the open market.
(These shares are included in the total, reported above.)
Details of these transactions:
(Date, Action, Quantity, Security, Description, Price, Amount, Trade Type)
12/12/2008 BOT 70,925 DNAG DNAPRINT GENOMICS IN $0.0004 -$28.37 Cash
12/11/2008 BOT 4,227,658 DNAG DNAPRINT GENOMICS INC $0.0004 -$1,691.06 Cash
12/03/2008 BOT 1,000,000 DNAG DNAPRINT GENOMICS INC $0.0004 -$400.00 Cash
11/25/2008 BOT 177,000 DNAG DNAPRINT GENOMICS INC $0.0004 -$70.80 Cash
11/21/2008 BOT 500 DNAG DNAPRINT GENOMICS INC $0.0004 -$0.20 Cash
11/20/2008 BOT 768,322 DNAG DNAPRINT GENOMICS INC $0.0004 -$307.33 Cash
11/19/2008 BOT 9,000,000 DNAG DNAPRINT GENOMICS INC $0.0004 -$3,600.00 Cash
11/19/2008 BOT 5,293,000 DNAG DNAPRINT GENOMICS INC $0.0004 -$2,117.20 Cash
11/19/2008 BOT 164,175 DNAG DNAPRINT GENOMICS INC $0.0004 -$65.67 Cash
(d)
Not applicable.
(e)
Not applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
RESPECT TO SECURITIES OF THE ISSUER
Not applicable.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
Not applicable.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
_____December 12, 2008_____
Date
_____Daniel Gannon_____
Signature
_____Individual Investor_____
Name/Title
|